Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + bortezomib + dexamethasone in first relapse or primary refractory multiple myeloma
NL-OMON23532Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Sep 2008; status: recruiting.
02
Drugs
lenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON23532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23532.